ADDED
As of May 1, 2025, the registrant had 49,414,707 shares of common stock outstanding.
Our business, business model, competitive strengths and growth strategy face various risks that are described in Part I, Item 1A.
2 The following summarizes the percent of our net revenues by segment during each of the past three fiscal years: March 31, 2025 2024 2023 Segment: North American OTC Healthcare 84.4 % 85.2 % 86.3 % International OTC Healthcare 15.6 14.8 13.7 Total 100.0 % 100.0 % 100.0 % For additional information concerning our business segments, please refer to Part II, Item 7.
Management s Discussion and Analysis of Financial Condition and Results of Operations and Note 18 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.
These brands accounted for approximately 83.0%, 83.3% and 81.9% of our total revenues for 2025, 2024, and 2023, respectively.
4 Market Position During 2025, approximately 61.5% of our total revenues were from major brands with a number one market position, compared with approximately 58.6% and 58.1% of total revenues during 2024 and 2023, respectively.
In 2025, these brands included BC and Goody's, Chloraseptic , Compound W , Debrox, Dramamine, Fess, Fleet, Gaviscon, Hydralyte, Monistat, Nix and Summer's Eve .
As an example of this philosophy, in 2025, we launched a number of new products, including Summer s Eve Whole Body Deodorant Creams in three fragrances, Goody s Plus Headache Pain + Mental Alertness and Dramamine Advanced Herbals For Kids.
In 2024, we launched Summer s Eve Ultimate Odor Protection line , Monistat's Maintain Boric Acid Suppositories, Clear Eyes Nighttime Restoring Drops and Dentek Gum Health Advanced Cleaning kit.
In 2025, we acquired additional rights to Hydralyte intellectual property in all remaining jurisdictions with the exception of the United States.
REMOVED
As of May 10, 2024, the registrant had 49,915,366 shares of common stock outstanding.
For more information, see Risk Factors contained in Part I, Item 1A of this Annual Report on Form 10-K.
Our business, business model, competitive strengths and growth strategy face various risks that are described in "Risk Factors" in Part I, Item 1A of this Annual Report on Form 10-K.
2 The following summarizes the percent of our net revenues by segment during each of the past three fiscal years: March 31, 2024 2023 2022 Segment: North American OTC Healthcare 85.2 % 86.3 % 89.1 % International OTC Healthcare 14.8 13.7 10.9 Total 100.0 % 100.0 % 100.0 % For additional information concerning our business segments, please refer to Part II, Item 7, Management s Discussion and Analysis of Financial Condition and Results of Operations and Note 20 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.
These brands accounted for approximately 83.3%, 81.9%, and 81.4% of our total revenues for 2024, 2023, and 2022, respectively.
4 Market Position During 2024, approximately 58.6% of our total revenues were from major brands with a number one market position, compared with approximately 58.1% and 67.5% of total revenues during 2023 and 2022, respectively.
In 2024, these brands included BC and Goody's, Chloraseptic , Compound W , Debrox, Dramamine, Fess, Fleet, Hydralyte, Monistat, Nix, and Summer's Eve .
As an example of this philosophy, in 2024 we launched a number of new products, including Summer s Eve Ultimate Odor Protection line , Monistat's Maintain Boric Acid Suppositories, Clear Eyes Nighttime Restoring Drops, and Dentek Gum Health Advanced Cleaning kit.
In 2023, we launched Summer s Eve Spa Renewing Wash, Compound W Total Care , Nix Lice Prevention Spray , Tagamet Cool Mint, and Fleet Fresh Clean Enemas.
Growing Our International Business International sales beyond the borders of North America represented 14.8%, 13.7% and 10.9% of total revenues in 2024, 2023, and 2022, respectively.